Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Vilma G Duschak
Trypanosoma cruzi, the causative agent of Chagas disease (ChD), contains a major antigen, cruzipain (Cz). Its C-terminal domain (C-T), bears several post-translational modifications The presence of sulfated oligosaccharides was demonstrated in Cz, in a minor antigen with serine-carboxypeptidase activity, and sulfatides Sulfate-bearing glycoproteins in Trypanosomatids are targets of specific immune responses. T. cruzi chronically-infected-subjects mount specific humoral immune responses to sulfated-Cz. In absence of infection, mice immunized with C-T- but not with sulfate-depleted-C-T, showed surprising ultrastructural heart pathological effects. Moreover, the synthetic anionic sugar conjugate NAcGlc6SO3 mimics the N-glycan-linked sulfated epitope (sulfotope) humoral response. Furthermore, the participation of sulfotopes in the immunomodulation by host-parasite interaction via sialic-acid-Ig-like-specific-lectins (Siglec) binding to sulfosialylated glycoproteins as well as in the parasite infection process has been reported. Strickingly, recent evidences involved to sulfotopes and their specific antibodies in the immunopathogenesis and infection processes of the experimental ChD. Interestingly, sera from chronically T. cruzi-infected individuals with mild disease displayed higher levels of IgG2 antibodies specific for sulfated glycoproteins and sulfatides compared with those in more severe forms of the disease, evidencing that T. cruzi sulfotopes are antigenic independently of the sulfated-glycoconjugate type. Ongoing assays indicate that antibodies specific for sulfotopes might play a role as predictors of stability from the early stages of chronic ChD and might be considered biomarkers of human ChD progression.